Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Alopecia Areata
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 29 more
Recruiting Phase 2 Interventional

JAK Signaling in Depression

NCT07003997
Conditions
Major Depressive Disorder
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
67
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 58 more
Conditions
Cutaneous Lichen Planus
Interventions
Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
Baricitinib
Drug
Lead sponsor
Raven Clinical Research
Network
Eligibility
18 Years to 75 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Marriottsville, Maryland • Fairfax, Virginia • McLean, Virginia + 1 more
Conditions
Rheumatoid Arthritis
Interventions
Active Stimulation, Sham Stimulation, Baricitinib, Background Treatment
Device · Drug
Lead sponsor
Galvani Bioelectronics
Industry
Eligibility
22 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
12
States / cities
Anniston, Alabama • Covina, California • Whittier, California + 8 more
Recruiting Phase 2 Interventional Accepts healthy volunteers

JAK Signaling in Depression and Cognition in Male Football Players

NCT07608796
Conditions
Depressive Symptoms, Cognitive Symptom
Interventions
Baricitinib
Drug
Lead sponsor
Emory University
Other
Eligibility
30 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3009104(Baricitinib) for Healthy Subjects

NCT01247350
Conditions
Healthy Volunteer
Interventions
LY3009104, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Graft-versus-host-disease, Graft Vs Host Disease
Interventions
Baricitinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 53 more
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Tucson, Arizona • Beverly Hills, California • Covina, California + 22 more
Conditions
Diabetic Kidney Disease
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
35
States / cities
Lancaster, California • San Diego, California • Torrance, California + 32 more
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Baricitinib Curative Repression of HIV-1

NCT07209267
Conditions
HIV Infection, HIV
Interventions
Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
COVID-19
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

NCT01870388
Conditions
Liver Diseases, Hepatic Insufficiency
Interventions
Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Conditions
Alopecia Areata
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 41 more